Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
Total Valuation
Revelation Biosciences has a market cap or net worth of $5.02M. The enterprise value is -$9.95B.
Market Cap$5.02M
Enterprise Value-$9.95B
Share Statistics
Revelation Biosciences has 3,720,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,720,420
Owned by Insiders56.11%
Owned by Institutions―
Financial Efficiency
Revelation Biosciences’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.09%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.09%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-1.11B
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revelation Biosciences is ―. Revelation Biosciences’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio0.03
Income Statement
In the last 12 months, Revelation Biosciences had revenue of 0.00 and earned -8.91M in profits. Earnings per share was -23.95.
Revenue0.00
Gross Profit-27.06K
Operating Income-9.07M
Pretax Income-8.91M
Net Income-8.91M
EBITDA18.14M
Earnings Per Share (EPS)-23.95
Cash Flow
In the last 12 months, operating cash flow was -8.27B and capital expenditures 0.00, giving a free cash flow of -8.27B billion.
Operating Cash Flow-8.27B
Free Cash Flow-8.27B
Free Cash Flow per Share-2.22K
Dividends & Yields
Revelation Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change-96.56%
50-Day Moving Average2.27
200-Day Moving Average6.64
Relative Strength Index (RSI)32.88
Average Volume (3m)740.56K
Important Dates
Revelation Biosciences upcoming earnings date is May 8, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Revelation Biosciences as a current ratio of 5.41, with Debt / Equity ratio of 8.43%
Current Ratio5.41
Quick Ratio5.41
Debt to Market Cap37.59
Net Debt to EBITDA-548.58
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Revelation Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Revelation Biosciences EV to EBITDA ratio is -547.48, with an EV/FCF ratio of 1.20.
EV to Sales0.00
EV to EBITDA-547.48
EV to Free Cash Flow1.20
EV to Operating Cash Flow1.20
Balance Sheet
Revelation Biosciences has $10.70B in cash and marketable securities with $746.78M in debt, giving a net cash position of $9.95B billion.
Cash & Marketable Securities$10.70B
Total Debt$746.78M
Net Cash$9.95B
Net Cash Per Share$2.68K
Tangible Book Value Per Share$1.43K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revelation Biosciences is $16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.00
Price Target Upside1677.78% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast96.26%